Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety run-in and Phase II Study of Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas

Trial Profile

A Safety run-in and Phase II Study of Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Avelumab (Primary) ; Bevacizumab (Primary) ; Epacadostat (Primary)
  • Indications Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Oct 2018 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
    • 05 Oct 2018 Planned End Date changed from 31 Aug 2023 to 31 Jan 2024.
    • 05 Oct 2018 Planned primary completion date changed from 31 May 2021 to 31 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top